AstraZeneca Plc said on Thursday its blood cancer treatment, Calquence, failed to meet the main goal of mid-stage trials, testing it in patients hospitalised with respiratory symptoms of Covid-19.
The drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its Covid-19 vaccine, developed in partnership with Oxford University, and its long-acting antibody combination.
Results from the trials will not impact approved indications or pending approvals for Calquence in patients with blood cancers, the company said.
(Published 12 November 2020, 08:17 IST)
JOIN US